PepGen (PEPG) Share-based Compensation (2021 - 2026)
PepGen (PEPG) posted Share-based Compensation of $2.9 million for Q1 2026, up 17.15% sequentially from $2.4 million in Q4 2025, and down 16.81% YoY from $3.4 million in Q1 2025.
Analysis
PepGen (PEPG) Share-based Compensation (2021 - 2026) Analysis & Trends
PepGen has reported Share-based Compensation for 6 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 16.81% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 13.73% YoY) and the FY2025 annual result came in at $15.8 million, down 46.8% from the prior year.
- Share-based Compensation improved to $2.9 million in Q1 2026 per PEPG's latest filing, from $2.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $25.6 million in Q2 2025 and troughed at $815000.0 in Q1 2022.
- A 5-year average of $4.8 million and a median of $2.4 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 3359.64% in 2022, then plunged 91.7% in 2023.
- Over 5 years, Share-based Compensation stood at $23.1 million in 2022, then slumped by 91.7% to $1.9 million in 2023, then soared by 74.14% to $3.3 million in 2024, then fell by 27.19% to $2.4 million in 2025, then rose by 17.15% to $2.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.9 million, $2.4 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 20.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.40 Mn |
| Mar 31, 2026 | 24.10 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 14.50 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 6.76 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 5.67 Mn |
| Jun 30, 2024 | 5.28 Mn |
| Mar 31, 2024 | 5.28 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Sep 30, 2023 | 4.17 Mn |
| Jun 30, 2023 | 4.22 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 23.15 Mn |
| Sep 30, 2022 | 3.37 Mn |
| Jun 30, 2022 | 3.21 Mn |
| Mar 31, 2022 | 2.08 Mn |
| Dec 31, 2021 | 669,000.00 |
| Sep 30, 2021 | 348,000.00 |